Global Medical REIT Inc.

Global Medical REIT Inc. (GMRE) Market Cap

Global Medical REIT Inc. has a market capitalization of .

No quote data available.

CEO: Mark O. Decker Jr.

Sector: Real Estate

Industry: REIT - Healthcare Facilities

IPO Date: 2016-06-30

Website: https://www.globalmedicalreit.com

Global Medical REIT Inc. (GMRE) - Company Information

Market Cap: -|Sector: Real Estate

Company Profile

Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.

Analyst Sentiment

72%
Strong Buy

From 9 Active Polls

1Y Forecast: $20.92

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$11

Median

$12

High Bound

$40

Average

$21

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$20.92
▼ -41.47% Upside
Low Target
$11.00
-69% Risk
Median Target
$11.75
-67% Mid
High Target
$40.00
12% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 GLOBAL MEDICAL REIT INC (GMRE) — Investment Overview

🧩 Business Model Overview

GLOBAL MEDICAL REIT INC operates as a specialized healthcare real estate owner, building and acquiring medical properties and leasing them to healthcare providers. The core value chain is straightforward: GMRE sources properties (including development and sale-leaseback opportunities), funds acquisitions and development, and monetizes the real estate through long-duration leases.

The economic design of the model emphasizes recurring cash flows. Most value is generated through property-level occupancy and lease contract quality (durable healthcare tenants, lease terms, and rent escalation features). The tenant’s operational requirements create practical friction to relocating, supporting lease durability and reducing churn versus more generic real estate.

💰 Revenue Streams & Monetisation Model

GMRE primarily earns rental income from its portfolio, with a structure that is typically designed to make income relatively stable across operating cycles (subject to lease terms and tenant credit). Monetisation is driven by:

  • Lease revenue durability: long lease terms and contractual rent mechanics support predictable cash generation.
  • Tenant performance and credit: lease collections depend on healthcare provider cash generation and balance sheet resilience.
  • Property expense pass-through (where structured): many medical REIT lease structures shift a portion of operating costs to tenants, reducing GMRE’s exposure to property-level cost inflation.
  • Renewals, re-leasing, and redevelopment: value creation often comes from maintaining or upgrading assets so that they remain functional and marketable to evolving outpatient needs.

Margin drivers in this sector are less about operating leverage and more about occupancy, lease terms, and credit quality, which collectively influence the stability of AFFO-style cash flows and dividend capacity.

🧠 Competitive Advantages & Market Positioning

GMRE’s competitive positioning is rooted in the intersection of healthcare demand and specialized real estate execution. The moat is primarily a combination of specialization-driven barriers to entry and tenant-level switching frictions.

  • High barriers to entry (specialized underwriting and deal sourcing): medical real estate requires domain knowledge around site functionality, provider operations, lease structuring, and credit evaluation. Competitors without the same underwriting focus can underprice risk or misjudge tenant durability.
  • Tenant “switching costs”: healthcare providers face operational disruption, licensing and regulatory complexity, patient continuity requirements, and build-out timelines if relocating. These frictions support lease retention and reduce probability of frequent tenant turnover.
  • Relationship-driven sourcing: medical REIT platforms build repeat access to provider relationships for leases, expansions, and refinancings—an intangible advantage that improves acquisition selectivity and lease quality.
  • Asset specialization: well-located, medically compatible facilities can be harder to replicate quickly, supporting long-run marketability.

Competitive benchmarking. Key peers and alternative capital providers in healthcare real estate include:

  • Medical Properties Trust (MPW): more concentrated in hospital-related exposures, often with different tenant and reimbursement risk dynamics.
  • Physicians Realty Trust (DOC) (or successor/combined structures in the space): similarly focused on medical office and outpatient facilities, competing on location selection, tenant mix, and lease structures.
  • Welltower (WELL): broader healthcare real estate footprint (including senior living and other settings), which competes for capital but operates with different property and operating drivers.

GMRE’s industry focus concentrates on medical real estate and the discipline of matching lease structures to tenant durability and property functionality, rather than broader healthcare categories with more operating-driven variability.

🚀 Multi-Year Growth Drivers

GMRE’s longer-horizon growth is supported by healthcare and real estate structural trends that are difficult to reverse:

  • Shift toward outpatient care: as procedures migrate to ambulatory settings, demand rises for appropriately designed clinics, imaging centers, and physician-linked facilities.
  • Demographics and healthcare utilization: an aging population increases chronic care requirements and office-based utilization, supporting demand for medical space.
  • Provider consolidation and balance-sheet optimization: continued ownership-model changes (including sale-leaseback and expansion financing) create a steady pipeline for leased property investment.
  • Facility modernization and functional obsolescence management: properties that can be adapted to evolving medical workflows can preserve cash flows, while less adaptable assets face higher vacancy and re-tenanting risk.
  • Local supply constraints: medical real estate demand is highly location-specific; zoning, site selection constraints, and permitting timelines limit quick replacement of well-situated assets.

Over a 5–10 year horizon, the opportunity set typically hinges on GMRE’s ability to sustain occupancy, expand via accretive acquisitions/development, and manage lease maturities and credit risk through a disciplined underwriting framework.

⚠ Risk Factors to Monitor

  • Tenant credit risk: healthcare providers can be pressured by payer reimbursement, patient volume volatility, labor costs, and capital expenditure needs—risks that may surface through lease coverage and renewal outcomes.
  • Lease rollover and re-leasing risk: concentration of lease expirations or a weaker demand environment for specific subtypes of medical space can raise vacancy and concession requirements.
  • Interest rate and refinancing risk: REIT performance depends on maintaining access to capital at reasonable spreads; higher cost of debt can reduce flexibility and increase funding costs.
  • Regulatory and reimbursement changes: CMS rules, state-level licensing, and reimbursement policy shifts can affect provider financial health and tenant durability.
  • Property obsolescence: if facilities cannot support evolving care delivery models (imaging, specialty workflows, technology integration), re-leasing may require costly upgrades.
  • Concentration risk: geographic, tenant-type, and payer-mix exposure can amplify downside if localized healthcare utilization trends deteriorate.

📊 Valuation & Market View

Healthcare REITs are commonly valued using cash-flow-oriented metrics rather than purely accounting earnings, including:

  • P/FFO or P/AFFO: reflecting expected normalized recurring cash generation.
  • EV/EBITDA (less central than FFO/AFFO but used by some investors): often paired with property-level cap rate assumptions.
  • NAV (Net Asset Value) approaches: discounting projected cash flows and considering underlying property value/cap rates.

Key drivers that typically move valuation for this sector include occupancy, lease term and rent escalation quality, tenant credit performance, leverage/interest coverage, and the market’s cap-rate environment. Consistent execution that supports durable cash flows tends to sustain valuation multiples; deterioration in credit or property liquidity typically compresses them.

🔍 Investment Takeaway

GLOBAL MEDICAL REIT INC fits a healthcare real estate model where value depends on durable leased cash flows, tenant-level switching frictions, and specialized execution. The investment case rests on the persistence of outpatient demand, provider behavior that favors continuity of care locations, and GMRE’s ability to underwrite and manage medical properties through lease cycles and credit environments.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"GMRE (Q1’26, ended 2026-03-31) reported Revenue of $38.1M and Net Income of -$0.7M (EPS -$0.06). On a QoQ basis, revenue increased to $38.1M from $35.2M in Q4’25 (+8.1% QoQ), while net losses widened to -$0.7M from -$11.8M (improvement of losses; -93.7% QoQ). On a YoY basis, revenue rose from $34.6M in Q1’25 to $38.1M (+10.0% YoY), but net income deteriorated from +$3.6M to -$0.7M (down 120.4% YoY). Profitability was weak in the most recent quarter: net margin was -1.97% versus -33.50% in Q4’25 (margin improvement QoQ), but below the +10.29% net margin in Q1’25 (YoY contraction). Operating cash flow remained positive at $13.4M, supporting a positive free cash flow of $13.4M in Q1’26. However, dividends remained high relative to earnings (dividends paid of -$10.9M), and the company is still loss-making in the quarter. Balance sheet resilience appears mixed. Total assets were $1.238B, broadly flat QoQ, but equity was $520.7M, modestly lower QoQ. Total shareholder returns cannot be robustly assessed because marketPerformance inputs are missing/undefined (price set to 0; 1Y change undefined)."

Revenue Growth

Positive

Revenue increased +8.1% QoQ (to $38.1M) and +10.0% YoY (from $34.6M). Growth is positive, though not enough to offset profitability deterioration YoY.

Profitability

Neutral

Net income swung to a loss in Q1’26 (-$0.7M) versus profit in Q1’25 (+$3.6M), a -120.4% YoY decline. QoQ losses improved (-93.7%), but net margin remains negative at -1.97%.

Cash Flow Quality

Fair

Operating cash flow was positive at $13.4M and free cash flow also positive ($13.4M). Nonetheless, dividends paid were substantial (-$10.9M) while earnings were negative, increasing reliance on cash generation/financing.

Leverage & Balance Sheet

Caution

Total assets were steady QoQ ($1.24B), but equity slightly declined to $520.7M. Losses persist (retained earnings remain deeply negative), indicating limited earnings-based strengthening.

Shareholder Returns

Neutral

Dividend yield is shown as ~2.50% in Q1’26, but total shareholder return assessment is constrained because marketPerformance price and 1Y change are undefined/0. No buybacks were reported in the quarter.

Analyst Sentiment & Valuation

Caution

Analyst targets show high dispersion (high $40 vs low $11; consensus ~$20.92). Without a valid current price input, upside/downside vs valuation cannot be quantified here.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

GMRE’s Q1 2026 call focused less on quarterly earnings and more on repositioning into a senior-housing growth platform. Management provided operating metrics (NAREIT FFO $0.97; Core FFO $1.11; same-store cash NOI +3.2% YoY; net debt/EBITDA 6.6x, down 0.4x YoY) while withdrawing 2026 guidance to avoid distraction from portfolio transition execution. The strategic centerpiece is new senior-housing capital partnerships with Silverstone and Greystone: Landing (stabilized cash flow), Riviera (early lease-up opened March 2026), and Pinnacle (175 homes; closing timing flexible Aug–Nov). Management underwrote yields >7% (untrended rents) and highlighted 100–150 bps cap-rate arbitrage versus the company’s implied cost of capital. A distribution cut to $0.16/month from July funds incremental capital ($15M/year). Funding hinges on LOI dispositions (IRF JV, CHRISTUS Beaumont, additional outpatient medical sales by Nov 1) and management expects earnings trough next quarter with stabilization rolling into 2027–2028, modeled for 2H 2028.

AI IconGrowth Catalysts

  • Repositioning into senior housing platform: >25% of asset value in SHOP after announced transactions (vs prior Feb plan)
  • Landing (163 homes) entering stabilized cash flow; burn-off of lease-up concessions after 2025 occupancy stabilization
  • Riviera (129 homes) newly delivered; opened March 2026 and in early lease-up
  • Pinnacle acquisition (175 homes) near completion in North Bethesda; contract allows closing timing fall (settlement windows Aug–Nov)
  • Underwritten senior housing yields in excess of 7% using untrended rents; potential for double-digit unlevered returns

Business Development

  • Silverstone Senior Living (developer/asset manager) as partner on Landing/Riviera/Pinnacle
  • Greystone to continue as operator across announced senior housing investments
  • Maewyn Capital Partners: $100 million strategic investment; Charles Fitzgerald expected to join Board later in May 2026
  • Federal Realty: Pinnacle located across from Federal Realty’s Pike & Rose (context for submarket/amenity strength, not a JV stated)
  • LOI disposition plans referenced: IRF JV and CHRISTUS asset in Beaumont, Texas

AI IconFinancial Highlights

  • NAREIT-defined FFO per share and unit: $0.97 for Q1 2026
  • Core FFO: $1.11 per share and unit
  • Net debt to adjusted EBITDA: 6.6x for the quarter, down 0.4x vs Q1 2025
  • Same-store cash NOI increased 3.2% YoY (includes assets owned 15+ months)
  • 2026 earnings guidance withdrawn to focus on portfolio transition; full-year expectations for cash/noncash G&A and capex-in-FAD stated as in line with prior communications
  • Capital recycling valuation arbitrage cited: implied ~9% cap rate in stock vs executed transactions at 7.3%–7.9% (100–150 bps advantage)
  • Dividend/distribution cut: monthly run rate reduced to $0.16/month ($1.92 annual run rate) starting July payment; provides $15 million additional capital per year

AI IconCapital Funding

  • Maewyn strategic investment: $100 million dedicated long-duration growth capital
  • Board-communicated funding math: ~300 million capital sources (Maewyn plus dispositions subject to LOI) to fund ~$425 million of identified investments
  • Pending/more imminent disposition sources under LOI: “a couple of hundred million” expected, with IRF JV as most likely use of proceeds, followed by CHRISTUS Beaumont
  • Outpatient medical dispositions expected by no later than November 1 to reach leverage-neutral proceeds
  • Net debt positioned at 6.6x adjusted EBITDA for the quarter (down 0.4x YoY); stated ultimate target is investment-grade access to bond market (company too small now)

AI IconStrategy & Ops

  • Repositioning from historically passive net lease ownership toward active capital recycling and external growth platform
  • Internal earnings progression designed by pairing stabilized Landing with lease-up Riviera
  • Capital allocation: reduce distribution to retain cash flow for self-funded accretive growth; avoid equity issuance at ~9% implied cap rate levels
  • Operational/portfolio execution priorities: close pending deals, integrate, execute underwritten lease-up performance, then continue capital recycling and sourcing
  • No store-closure/supply-chain operational details provided; focus remained on portfolio transition execution

AI IconMarket Outlook

  • 2026 earnings guidance withdrawn (withdrawal reason: portfolio transition focus, not negative events)
  • Management cited trough in earnings performance: “present trough is probably next quarter”
  • Long-term stabilization timeline: start stabilizing in 2027–2028; company expects to “put it… in our book second half of 2028”

AI IconRisks & Headwinds

  • Execution risk during repositioning: lease-up performance and concession burn-off timing for Riviera/transition assets
  • Funding/timing risk: reliance on LOI dispositions (IRF JV, CHRISTUS Beaumont, additional outpatient medical sales) by fall/through November 1 to reach leverage-neutral proceeds
  • Competitive risk in senior housing: higher-velocity auction dynamics where price certainty dominates; management claims reduced participation in auctions but competition from larger REITs still implied
  • Leverage/ratings risk: company too small for immediate bond market access; ultimate investment-grade target depends on stabilization and opportunity flow

Q&A: Analyst Interest

  • Funding bridge: Management confirmed they have financing coverage for the ~ $425M announced investments via “a couple of hundred million under LOI,” citing IRF JV as primary proceeds and CHRISTUS Beaumont following; additionally, they expect other outpatient medical dispositions through November 1 to reach leverage-neutral proceeds.
  • Senior housing niche/competition: Management said Chiron avoids competing “in an auction” where sellers optimize only price and speed. Instead, it competes by being “thoughtful and creative,” listening for solution design, and building operator/developer win-wins, which they characterized as harder but achievable (Silverstone example).
  • Earnings growth timing: Management linked a referenced 6% long-term earnings growth goal to funding and execution. They stated the “present trough” is likely next quarter, with stabilization beginning in 2027–2028, and that the model assumes stability reflected in their book during second half of 2028.

Sentiment: MIXED

Note: This summary was synthesized by AI from the GMRE Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Global Medical REIT Inc. (GMRE) Financial Profile